Please login to the form below

Not currently logged in
Email:
Password:

CINV

This page shows the latest CINV news and features for those working in and with pharma, biotech and healthcare.

Acacia eyes February FDA verdict for refiled nausea drug Barhemsys

Acacia eyes February FDA verdict for refiled nausea drug Barhemsys

and vomiting (CINV). ... The CINV product – APD403 – has completed one proof-of-concept and one phase 2 dose-ranging study, and Acacia says it intends to start phase 3 trials after completion of an

Latest news

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    Relypsa. USA. rolapitant. Varubi. chemotherapy-induced nausea and vomiting (CINV). neurokinin-1 receptor antagonist.

  • Merck plans expanded filing for Emend this year Merck plans expanded filing for Emend this year

    Merck &Co's nausea and vomiting therapy Emend is effective in preventing chemotherapy-induced nausea and vomiting (CINV) even when given as a single dose, says a new study. ... Generics aside, competition is building in the CINV sector. Last October the

  • GSK files NDA in the US

    FDA). The drug performed well during trials, with results showing that it significantly reduced the number of patients who experienced CINV. ... The company said that 40 to 50 per cent of patients still succumb to breakthrough CINV despite being on

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency. We dispense pioneering and creative campaigns, driven by...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics